IGC
IGC Pharma, Inc.
Price Chart
Latest Quote
$0.27
+0.00 (+1.28%)
Current Price
| Previous Close | $0.27 |
| Open | $0.27 |
| Day High | $0.28 |
| Day Low | $0.27 |
| Volume | 306,164 |
Stock Information
| Shares Outstanding | 100.09M |
| Total Debt | $926K |
| Cash Equivalents | $235K |
| Revenue | $1.11M |
| Net Income | $-6.45M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $26.86M |
| EPS (TTM) | $-0.06 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $27.56M |
| Sales | $1.11M |
| Income | $-6.45M |
| Book/sh | $0.06 |
| Cash/sh | $0.00 |
| Employees | 70 |
Financial Ratios
| Quick Ratio | 0.79 |
| Current Ratio | 1.32 |
| Debt/Eq | 15.13 |
Returns & Margins
| ROA | -50.31% |
| ROE | -83.34% |
| Gross Margin | 46.20% |
| Operating Margin | -722.71% |
Ownership
| Insider Ownership | 9.68% |
| Institutional Ownership | 22.51% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.16 |
| P/S | 24.29 |
| P/B | 4.33 |
Analyst Data
| Recommendation | none |
| Target Price | $4.25 |
Technical Indicators
| SMA20 | $0.28 |
| SMA50 | $0.30 |
| SMA200 | $0.32 |
| RSI | 20.00 |
| ATR | 0.0129 |
| Shares Float | 90.22M |
| Short Float | 2.05% |
| Short Ratio | 1.89 |
| Volatility | 0.45 |
| Rel Volume | 0.49 |
Performance History
| Week | -3.57% |
| Month | -6.90% |
| Quarter | +8.00% |
| 6 Months | -10.00% |
| YTD | -6.90% |
| Year | -12.90% |
| 3 Years | -12.90% |
| 5 Years | -83.02% |
| 10 Years | -46.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $0.27 | 306,900 |
| 2026-06-23 | $0.27 | 706,900 |
| 2026-06-22 | $0.27 | 496,900 |
| 2026-06-18 | $0.27 | 631,200 |
| 2026-06-17 | $0.28 | 1,067,600 |
| 2026-06-16 | $0.28 | 854,400 |
| 2026-06-15 | $0.28 | 682,100 |
| 2026-06-12 | $0.28 | 565,000 |
| 2026-06-11 | $0.28 | 578,100 |
| 2026-06-10 | $0.28 | 242,300 |
| 2026-06-09 | $0.29 | 1,308,700 |
| 2026-06-08 | $0.30 | 630,600 |
| 2026-06-05 | $0.29 | 453,600 |
| 2026-06-04 | $0.29 | 479,100 |
| 2026-06-03 | $0.30 | 1,600,100 |
| 2026-06-02 | $0.29 | 412,400 |
| 2026-06-01 | $0.30 | 491,600 |
| 2026-05-29 | $0.29 | 261,800 |
| 2026-05-28 | $0.29 | 288,900 |
| 2026-05-27 | $0.29 | 442,500 |
| 2026-05-26 | $0.29 | 318,100 |
About IGC Pharma, Inc.
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
đ° Latest News
IGC Pharma, New to The Street launch 12-part national media partnership
TipRanks âĸ 2026-03-26T12:20:15Z
electroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates
Zacks âĸ 2026-03-19T21:45:02Z
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
Zacks âĸ 2026-03-18T21:25:01Z
Merck KGaA (MKKGY) Lags Q4 Earnings Estimates
Zacks âĸ 2026-03-05T12:05:02Z
IGC Pharma expands Phase 2 CALMA trial with new clinical site
TipRanks âĸ 2026-02-24T13:49:20Z
Trump expected to sign EO to reclassify marijuana as soon as Monday, CNBC says
TipRanks âĸ 2025-12-13T16:15:27Z
IGC Pharma Inc (IGC) Q2 2026 Earnings Call Highlights: Strategic Advances and Financial Maneuvers
GuruFocus.com âĸ 2025-11-17T23:00:31Z
IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates
Zacks âĸ 2025-11-14T22:30:16Z
Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates
Zacks âĸ 2025-11-13T22:20:02Z
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
Zacks âĸ 2025-11-12T22:15:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $652,000 | $612,000 | $469,000 | $203,000 |
| Cost Of Revenue | $652,000 | $612,000 | $469,000 | $203,000 |
| Total Revenue | $1,271,000 | $1,345,000 | $911,000 | $397,000 |
| Operating Revenue | $1,271,000 | $1,181,000 | $911,000 | $397,000 |
| Expenses | ||||
| Total Expenses | $8,717,000 | $11,143,000 | $12,482,000 | $15,825,000 |
| Other Income Expense | $325,000 | $-3,202,000 | $65,000 | $412,000 |
| Other Non Operating Income Expenses | $325,000 | $143,000 | $65,000 | $461,000 |
| Operating Expense | $8,065,000 | $10,531,000 | $12,013,000 | $15,622,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-7,121,000 | $-13,000,000 | $-11,506,000 | $-15,016,000 |
| Normalized Income | $-7,121,000 | $-9,655,000 | $-11,506,000 | $-14,967,000 |
| Net Income From Continuing And Discontinued Operation | $-7,121,000 | $-13,000,000 | $-11,506,000 | $-15,016,000 |
| Total Operating Income As Reported | $-7,446,000 | $-9,798,000 | $-11,571,000 | $-15,428,000 |
| Net Income Common Stockholders | $-7,121,000 | $-13,000,000 | $-11,506,000 | $-15,016,000 |
| Net Income | $-7,121,000 | $-13,000,000 | $-11,506,000 | $-15,016,000 |
| Net Income Including Noncontrolling Interests | $-7,121,000 | $-13,000,000 | $-11,506,000 | $-15,016,000 |
| Net Income Continuous Operations | $-7,121,000 | $-13,000,000 | $-11,506,000 | $-15,016,000 |
| Pretax Income | $-7,121,000 | $-13,000,000 | $-11,506,000 | $-15,016,000 |
| Special Income Charges | $0 | $-3,345,000 | $0 | $-49,000 |
| Operating Income | $-7,446,000 | $-9,798,000 | $-11,571,000 | $-15,428,000 |
| Gross Profit | $619,000 | $733,000 | $442,000 | $194,000 |
| Per Share | ||||
| Diluted EPS | $-0.09 | $-0.22 | $-0.22 | $-0.30 |
| Basic EPS | $-0.09 | $-0.22 | $-0.22 | $-0.30 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-6,982,000 | $-5,816,000 | $-10,914,000 | $-14,728,000 |
| Total Unusual Items | $0 | $-3,345,000 | $0 | $-49,000 |
| Total Unusual Items Excluding Goodwill | $0 | $-3,345,000 | $0 | $-49,000 |
| Reconciled Depreciation | $464,000 | $637,000 | $657,000 | $651,000 |
| EBITDA (Bullshit earnings) | $-6,982,000 | $-9,161,000 | $-10,914,000 | $-14,777,000 |
| EBIT | $-7,446,000 | $-9,798,000 | $-11,571,000 | $-15,428,000 |
| Diluted Average Shares | $76,517,175 | $58,839,868 | $52,576,258 | $49,991,631 |
| Basic Average Shares | $76,517,175 | $58,839,868 | $52,576,258 | $49,991,631 |
| Diluted NI Availto Com Stockholders | $-7,121,000 | $-13,000,000 | $-11,506,000 | $-15,016,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Impairment Of Capital Assets | $0 | $3,345,000 | $0 | - |
| Research And Development | $3,655,000 | $3,773,000 | $3,461,000 | $2,330,000 |
| Selling General And Administration | $4,410,000 | $6,758,000 | $8,552,000 | $13,292,000 |
| Write Off | - | - | $0 | $49,000 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $4,478,000 | $5,705,000 | $13,741,000 | $22,975,000 |
| Total Assets | $8,747,000 | $9,902,000 | $17,178,000 | $26,834,000 |
| Total Non Current Assets | $5,851,000 | $6,197,000 | $10,712,000 | $11,723,000 |
| Non Current Prepaid Assets | $1,000 | $2,000 | $52,000 | $569,000 |
| Non Current Accounts Receivable | $680,000 | $686,000 | $951,000 | $368,000 |
| Goodwill And Other Intangible Assets | $1,852,000 | $1,616,000 | $1,170,000 | $917,000 |
| Other Intangible Assets | $1,852,000 | $1,616,000 | $1,170,000 | $917,000 |
| Current Assets | $2,896,000 | $3,705,000 | $6,466,000 | $15,111,000 |
| Other Current Assets | $342,000 | $115,000 | $262,000 | $336,000 |
| Assets Held For Sale Current | $702,000 | $720,000 | $0 | - |
| Prepaid Assets | $10,000 | $41,000 | $72,000 | $170,000 |
| Inventory | $1,360,000 | $1,540,000 | $2,651,000 | $3,548,000 |
| Receivables | $77,000 | $91,000 | $131,000 | $597,000 |
| Other Receivables | $43,000 | $52,000 | $24,000 | $472,000 |
| Accounts Receivable | $34,000 | $39,000 | $107,000 | $125,000 |
| Allowance For Doubtful Accounts Receivable | $-12,000 | $-24,000 | $-17,000 | $-93,000 |
| Gross Accounts Receivable | $46,000 | $63,000 | $124,000 | $218,000 |
| Cash Cash Equivalents And Short Term Investments | $405,000 | $1,198,000 | $3,350,000 | $10,460,000 |
| Cash And Cash Equivalents | $405,000 | $1,198,000 | $3,196,000 | $10,460,000 |
| Cash Equivalents | $37,000 | $286,000 | $2,040,000 | - |
| Cash Financial | $368,000 | $912,000 | $1,156,000 | - |
| Debt | ||||
| Total Debt | $238,000 | $345,000 | $481,000 | $608,000 |
| Long Term Debt And Capital Lease Obligation | $144,000 | $221,000 | $348,000 | $485,000 |
| Long Term Debt | $134,000 | $137,000 | $141,000 | $144,000 |
| Current Debt And Capital Lease Obligation | $94,000 | $124,000 | $133,000 | $123,000 |
| Current Debt | - | - | - | $3,000 |
| Other Current Borrowings | - | - | - | $3,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,417,000 | $2,581,000 | $2,267,000 | $2,942,000 |
| Total Non Current Liabilities Net Minority Interest | $160,000 | $241,000 | $369,000 | $501,000 |
| Other Non Current Liabilities | $16,000 | - | - | - |
| Current Liabilities | $2,257,000 | $2,340,000 | $1,898,000 | $2,441,000 |
| Other Current Liabilities | $1,003,000 | $419,000 | $358,000 | $180,000 |
| Payables And Accrued Expenses | $883,000 | $773,000 | $530,000 | $981,000 |
| Payables | $883,000 | $773,000 | $530,000 | $981,000 |
| Accounts Payable | $883,000 | $773,000 | $530,000 | $981,000 |
| Equity | ||||
| Common Stock Equity | $6,330,000 | $7,321,000 | $14,911,000 | $23,892,000 |
| Total Equity Gross Minority Interest | $6,330,000 | $7,321,000 | $14,911,000 | $23,892,000 |
| Stockholders Equity | $6,330,000 | $7,321,000 | $14,911,000 | $23,892,000 |
| Gains Losses Not Affecting Retained Earnings | $-3,496,000 | $-3,423,000 | $-3,389,000 | $-2,968,000 |
| Other Equity Adjustments | $-3,496,000 | $-3,423,000 | $-3,389,000 | $-2,968,000 |
| Retained Earnings | $-120,744,000 | $-113,665,000 | $-100,665,000 | $-89,159,000 |
| Other | ||||
| Ordinary Shares Number | $80,878,058 | $66,691,195 | $53,077,436 | $51,054,017 |
| Share Issued | $80,878,058 | $66,691,195 | $53,077,436 | $51,054,017 |
| Tangible Book Value | $4,478,000 | $5,705,000 | $13,741,000 | $22,975,000 |
| Invested Capital | $6,464,000 | $7,458,000 | $15,052,000 | $24,036,000 |
| Working Capital | $639,000 | $1,365,000 | $4,568,000 | $12,670,000 |
| Capital Lease Obligations | $104,000 | $208,000 | $340,000 | $464,000 |
| Total Capitalization | $6,464,000 | $7,458,000 | $15,052,000 | $24,036,000 |
| Capital Stock | $130,570,000 | $124,409,000 | $118,965,000 | $116,019,000 |
| Common Stock | $130,570,000 | $124,409,000 | $118,965,000 | $116,019,000 |
| Long Term Capital Lease Obligation | $10,000 | $84,000 | $207,000 | $341,000 |
| Long Term Provisions | $16,000 | $20,000 | $21,000 | $16,000 |
| Current Capital Lease Obligation | $94,000 | $124,000 | $133,000 | $123,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $160,000 | $816,000 | $619,000 | $1,054,000 |
| Current Provisions | $117,000 | $208,000 | $258,000 | $103,000 |
| Net PPE | $3,318,000 | $3,893,000 | $8,539,000 | $9,869,000 |
| Accumulated Depreciation | $-2,693,000 | $-2,442,000 | $-1,936,000 | $-3,220,000 |
| Gross PPE | $6,011,000 | $6,335,000 | $10,475,000 | $13,089,000 |
| Other Properties | $98,000 | $198,000 | $326,000 | $450,000 |
| Machinery Furniture Equipment | $3,572,000 | $3,834,000 | $3,751,000 | $5,283,000 |
| Buildings And Improvements | $2,439,000 | $2,303,000 | $2,298,000 | $2,810,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $256,000 | $441,000 | $533,000 | $717,000 |
| Raw Materials | $1,104,000 | $1,099,000 | $2,100,000 | $2,247,000 |
| Other Short Term Investments | $0 | $0 | $154,000 | $0 |
| Treasury Shares Number | - | $0 | - | - |
| Construction In Progress | - | $0 | $0 | $108,000 |
| Land And Improvements | - | $0 | $4,100,000 | $4,438,000 |
| Work In Process | - | $0 | $18,000 | $584,000 |
| Investments And Advances | - | - | - | $0 |
| Other Investments | - | - | - | $0 |
| Preferred Stock | - | - | - | - |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-4,381,000 | $-5,714,000 | $-7,666,000 | $-8,233,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-4,065,000 | $-5,199,000 | $-7,047,000 | $-7,462,000 |
| Cash Flow From Continuing Operating Activities | $-4,065,000 | $-5,199,000 | $-7,047,000 | $-7,462,000 |
| Operating Gains Losses | $-14,000 | $-44,000 | $39,000 | $-430,000 |
| Investing Activities | ||||
| Capital Expenditure | $-316,000 | $-515,000 | $-619,000 | $-771,000 |
| Investing Cash Flow | $-300,000 | $-317,000 | $-235,000 | $-742,000 |
| Cash Flow From Continuing Investing Activities | $-300,000 | $-317,000 | $-235,000 | $-742,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $3,649,000 | $3,527,000 | $103,000 | $4,145,000 |
| Financing Cash Flow | $3,646,000 | $3,524,000 | $100,000 | $4,142,000 |
| Cash Flow From Continuing Financing Activities | $3,646,000 | $3,524,000 | $100,000 | $4,142,000 |
| Net Common Stock Issuance | $3,649,000 | $3,527,000 | $103,000 | $4,145,000 |
| Common Stock Issuance | $3,649,000 | $3,527,000 | $103,000 | $4,145,000 |
| Other | ||||
| Repayment Of Debt | $-3,000 | $-3,000 | $-3,000 | $-3,000 |
| End Cash Position | $470,000 | $1,198,000 | $3,196,000 | $10,460,000 |
| Beginning Cash Position | $1,198,000 | $3,196,000 | $10,460,000 | $14,548,000 |
| Effect Of Exchange Rate Changes | $-9,000 | $-6,000 | $-82,000 | $-26,000 |
| Changes In Cash | $-719,000 | $-1,992,000 | $-7,182,000 | $-4,062,000 |
| Net Issuance Payments Of Debt | $-3,000 | $-3,000 | $-3,000 | $-3,000 |
| Net Long Term Debt Issuance | $-3,000 | $-3,000 | $-3,000 | $-3,000 |
| Long Term Debt Payments | $-3,000 | $-3,000 | $-3,000 | $-3,000 |
| Net Investment Purchase And Sale | $0 | $154,000 | $-154,000 | $0 |
| Purchase Of Investment | $0 | - | $-154,000 | $0 |
| Net Intangibles Purchase And Sale | $-222,000 | $-377,000 | $-309,000 | $-535,000 |
| Purchase Of Intangibles | $-222,000 | $-377,000 | $-309,000 | $-535,000 |
| Net PPE Purchase And Sale | $-78,000 | $-94,000 | $228,000 | $-207,000 |
| Sale Of PPE | $16,000 | $44,000 | $538,000 | $29,000 |
| Purchase Of PPE | $-94,000 | $-138,000 | $-310,000 | $-236,000 |
| Change In Working Capital | $224,000 | $1,894,000 | $794,000 | $2,536,000 |
| Change In Other Current Liabilities | $-72,000 | $-123,000 | $-134,000 | $-64,000 |
| Change In Other Current Assets | $76,000 | $444,000 | $-26,000 | $-296,000 |
| Change In Payables And Accrued Expense | $313,000 | $440,000 | $-539,000 | $375,000 |
| Change In Accrued Expense | $251,000 | $197,000 | $-88,000 | $-129,000 |
| Change In Payable | $62,000 | $243,000 | $-451,000 | $504,000 |
| Change In Account Payable | $62,000 | $243,000 | $-451,000 | $504,000 |
| Change In Prepaid Assets | $-190,000 | $150,000 | $591,000 | $541,000 |
| Change In Inventory | $107,000 | $1,008,000 | $897,000 | $1,930,000 |
| Change In Receivables | $-10,000 | $-25,000 | $5,000 | $50,000 |
| Changes In Account Receivables | $-10,000 | $-25,000 | $5,000 | $50,000 |
| Stock Based Compensation | $1,185,000 | $1,773,000 | $2,843,000 | $2,197,000 |
| Provisionand Write Offof Assets | $0 | $93,000 | $126,000 | $1,718,000 |
| Asset Impairment Charge | $0 | $3,448,000 | $0 | $882,000 |
| Depreciation Amortization Depletion | $464,000 | $637,000 | $657,000 | $651,000 |
| Depreciation And Amortization | $464,000 | $637,000 | $657,000 | $651,000 |
| Gain Loss On Sale Of PPE | $-25,000 | $-44,000 | $39,000 | $0 |
| Net Income From Continuing Operations | $-5,924,000 | $-13,000,000 | $-11,506,000 | $-15,016,000 |
| Amortization Cash Flow | - | $74,000 | - | - |
| Amortization Of Intangibles | - | $74,000 | - | - |
| Depreciation | - | $563,000 | - | - |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Sale Of Investment | - | - | - | $0 |
| Other Non Cash Items | - | - | - | $-430,000 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Change In Other Working Capital | - | - | - | - |
Fetched: 2026-06-24